Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888301 | 0.90 | ADORA3 (0.39) | ADORA3NPC1RAB9ASMN1; SMN2ESR1 | |
| SCHEMBL12887445 | 0.90 | ADORA3 (0.39) | ADORA3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12888279 | 0.87 | ADORA3 (0.42) | ADORA3MAPT | |
| SCHEMBL12888347 | 0.86 | ADORA3 (0.45) | ADORA3NPC1RAB9AMAPTESR1 | |
| SCHEMBL12888413 | 0.86 | ADORA3 (0.36) | ADORA3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12884962 | 0.85 | KMO (0.38) | PDE4BPDE4D | |
| SCHEMBL12887446 | 0.82 | ADORA3 (0.35) | ADORA3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12888398 | 0.81 | MAPT (0.42) | ADORA3NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12887486 | 0.81 | KDM4E (0.41) | ADORA3MAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL12888234 | 0.81 | KMO (0.37) | PDE4BPDE4DSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575338-B2 | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-02-10 | — | — | US | disclosed |
| WO-2009125870-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS. | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034435-A1 | PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS | KCNJ2, KCNJ1, KCNJ11 | ADORA3 608/4885NPC1 2843/4885RAB9A 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.